Management of metastatic renal cell carcinoma has been enriched by the advent of new therapeutic compounds. The approval of new combination strategies between targeted agents and immune-checkpoint inhibitors as well as the administration of combinations between immune-checkpoint inhibitors has clearly demonstrated significant improvement toward patients' prognosis and other clinical outcomes. Due to the availability of different treatments, the choice between them may be a difficult issue in our clinical practice. We have summarized current knowledge about available treatments focusing on criteria, which may help clinicians to make decisions.
Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice / Massari, F.; Nunno, V. D.; Mollica, V.; Montironi, R.; Cheng, L.; Cimadamore, A.; Blanca, A.; Lopez-Beltran, A.. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - 11:17(2019), pp. 1507-1521. [10.2217/imt-2019-0115]